Overview Of Non-Therapeutic Antibiotics for Food Animals Market
Non-therapeutic antibiotics are administered at sub therapeutic levels in order to increase feed conversion rate. In order to have better margins livestock farmers administer the antibiotics in very low quantity through water especially in poultry and swine. Compound feed manufacturers and feed premix manufacturers are also adding antibiotics to make sure, their feed and ingredients give maximum profit to its buyers. However, such practice has led to development of antibiotic resistant pathogens and hence are being banned in many countries and also controversy on its uses are increasing progressively. Thus the growth of antibiotics in many countries are being plateaued out and in others growth may prematurely can plateaued or even drastically fall. The New Non-Therapeutic Antibiotics for Food Animals Market Research Analysis provides a detailed overview, Shares, Strategy, and Forecasts of the Non-Therapeutic Antibiotics for Food Animals market and delivers a comprehensive individual analysis on the top companies, including AG Zoetis, Inc., Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck & Co., Inc., Bayer AG, AG Sanofi, Ceva Sante Animale, Virbac, Vetoquinol S.A., Dechra Pharmaceuticals
The Non-Therapeutic Antibiotics for Food Animals market is anticipated to grow at a CAGR of about XX% over the forecast period, i.e., 2021-2028. The market is expected to reach USD XX million by the end of 2028.
The report provides valuable data on global Non-Therapeutic Antibiotics for Food Animals industry. Present and historical as well as future trends of global and countries markets are considered. Also Report complete study of current trends in the Non-Therapeutic Antibiotics for Food Animals market, industry growth drivers, and restraints. It provides Non-Therapeutic Antibiotics for Food Animals market projections for the coming years. It includes analysis of recent developments in technology, Porter\'s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Key Companies
AG Zoetis, Inc.
Boehringer Ingelheim GmbH
Eli Lilly and Company
Merck & Co., Inc.
Bayer AG
AG Sanofi
Ceva Sante Animale
Virbac
Vetoquinol S.A.
Dechra Pharmaceuticals
Market Product Type Segmentation
Oxytetracyclines
Tylosin
Ampicillin and Amoxycillin
Gentamicin
Sulfaquinoxaline
Salinomycin
Bacitracin
Others
Market by Application Segmentation
Cattle Feed
Poultry Feed
Swine Feed
Aqua Feed
Others
By Region
Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America [United States, Canada, Mexico]
Middle East & Africa [GCC, North Africa, South Africa]
South America [Brazil, Argentina, Columbia, Chile, Peru]
The research provides answers to the following key questions:
• What is the size of occupied by the prominent leaders for the forecast period, 2021 to 2028?
• What will be the share and the growth rate of the Non-Therapeutic Antibiotics for Food Animals market during the forecast period?
• What are the future prospects for the Non-Therapeutic Antibiotics for Food Animals industry in the coming years?
• Which trends are likely to contribute to the development rate of the industry during the forecast period, 2021 to 2028?
• What are the future prospects of the Non-Therapeutic Antibiotics for Food Animals industry for the forecast period, 2021 to 2028?
• Which companies are dominating the competitive landscape across different region and what strategies have they applied to gain a competitive edge?
• What are the major factors responsible for the growth of the market across the different regions?
• What are the challenges faced by the companies operating in the Non-Therapeutic Antibiotics for Food Animals market?
Note – In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.